trial

Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

NCTId NCT00088049
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 560
Sponsored by Eli Lilly and Company
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
560
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2003-10
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
OlanzapineAripiprazole

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

24 total
Little Rock, United StatesGarden Grove, United StatesNational City, United StatesOrange, United StatesFort Lauderdale, United StatesHollywood, United StatesTampa, United StatesAtlanta, United StatesChicago, United StatesOakbrook Terrace, United StatesNew Orleans, United StatesGlen Burnie, United States

Facts & assertions

3 sourced
Enrollment
560
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Aripiprazole
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person